Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Current Deferred Revenue for 10 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.7 million for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.7 million at Akebia Therapeutics, down from $3.9 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $75.8 million in Q1 2022, with the low at $1.2 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $35.6 million, with a median of $43.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 323.8% in 2021, then tumbled 97.18% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $42.4 million in 2021, then grew by 10.98% to $47.0 million in 2022, then dropped by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then crashed by 93.81% to $2.7 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.7 million, $3.9 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.